Induction of thymidylate synthase associated with multidrug resistance in human breast and colon cancer cell lines

E. Chu, J. C. Drake, D. M. Koeller, S. Zinn, Carlos Alberto Jamis-Dow, G. C. Yeh, C. J. Allegra

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

A series of Adriamycin-resistant human breast MCF-7 and human colon DLD-1 cancer cell lines were established by stepwise selection. The concentration of Adriamycin required to inhibit cell proliferation by 50% (IC50) in the parent breast line (MCF-7), Adriamycin-resistant lines (MCF-Ad5 and MCF-Adl 0), and a 5-fluorouracil (5-FU)-revertant line (MCF-R) was 0.005, 3.3, 6, and 4.9 μM, respectively. The Adriamycin IC50 value for the resistant colon line (DLD-Ad) was 8.2 μM, 68-fold higher than that for its parent line (DLD-1) (IC50 = 0.12 μM). The MCF-Ad5 and MCF-Ad10 cells were cross-resistant to 5-FU, with respective 5-FU IC50 values of 11.7 and 22.5 μM, or 7.3- and 14-fold less sensitive than their parent MCF-7 (IC50 = 1.6 μM) line. The MCF-R line completely reverted in sensitivity to 5-FU, with an IC50 of 1.7 μM. The resistant DLD-Ad line was 3.5-fold more resistant to 5-FU than was the parent DLD-1 line. Using both the 5-fluoro-2'-deoxyuridine-5'-monophosphate binding and catalytic assays for measurement of thymidylate synthase (TS) activity, there was significantly increased TS activity in the resistant MCF-Ad5 (2.4 and 2.5-fold), MCF-Ad10 (11.5- and 6.8-fold), and DLD-Ad (4.8- and 10.7-fold) lines, for binding and catalytic assays, respectively, compared with their parent MCF-7 and DLD-1 lines. The level of TS in cytosolic extracts, as determined by Western immunoblot analysis, was markedly increased for the resistant MCF-Ad5 (31-fold), MCF-Ad10 (46-fold), and DLD-Ad (52-fold) cells. Measurement of TS mRNA levels by Northern analysis revealed elevation of TS mRNA in the resistant MCF-AD5 (16.7-fold), MCF-Ad10 (31-fold), and DLD-Ad (55-fold) cells. Southern analysis showed that this increase in TS mRNA was not accompanied by any major rearrangements or amplification of the TS gene. Incorporation of 5-FU into the RNA and DNA of the resistant MCF-Ad10 cells was not significantly different, compared with that for parent MCF-7 cells. These studies suggest that exposure of human breast and human colon cancer cells to Adriamycin leads to overexpression of TS, with concomitant development of resistance to 5-FU.

Original languageEnglish (US)
Pages (from-to)136-143
Number of pages8
JournalMolecular Pharmacology
Volume39
Issue number2
StatePublished - Jan 1 1991

Fingerprint

Thymidylate Synthase
Multiple Drug Resistance
Colonic Neoplasms
Fluorouracil
Breast Neoplasms
Inhibitory Concentration 50
Cell Line
Doxorubicin
Breast
Messenger RNA
Colon
Fluorodeoxyuridylate
MCF-7 Cells
Western Blotting
Cell Proliferation
Alzheimer Disease 10
RNA
DNA

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology

Cite this

Chu, E., Drake, J. C., Koeller, D. M., Zinn, S., Jamis-Dow, C. A., Yeh, G. C., & Allegra, C. J. (1991). Induction of thymidylate synthase associated with multidrug resistance in human breast and colon cancer cell lines. Molecular Pharmacology, 39(2), 136-143.
Chu, E. ; Drake, J. C. ; Koeller, D. M. ; Zinn, S. ; Jamis-Dow, Carlos Alberto ; Yeh, G. C. ; Allegra, C. J. / Induction of thymidylate synthase associated with multidrug resistance in human breast and colon cancer cell lines. In: Molecular Pharmacology. 1991 ; Vol. 39, No. 2. pp. 136-143.
@article{8bba5947351b4afc9f2a791963ef94ce,
title = "Induction of thymidylate synthase associated with multidrug resistance in human breast and colon cancer cell lines",
abstract = "A series of Adriamycin-resistant human breast MCF-7 and human colon DLD-1 cancer cell lines were established by stepwise selection. The concentration of Adriamycin required to inhibit cell proliferation by 50{\%} (IC50) in the parent breast line (MCF-7), Adriamycin-resistant lines (MCF-Ad5 and MCF-Adl 0), and a 5-fluorouracil (5-FU)-revertant line (MCF-R) was 0.005, 3.3, 6, and 4.9 μM, respectively. The Adriamycin IC50 value for the resistant colon line (DLD-Ad) was 8.2 μM, 68-fold higher than that for its parent line (DLD-1) (IC50 = 0.12 μM). The MCF-Ad5 and MCF-Ad10 cells were cross-resistant to 5-FU, with respective 5-FU IC50 values of 11.7 and 22.5 μM, or 7.3- and 14-fold less sensitive than their parent MCF-7 (IC50 = 1.6 μM) line. The MCF-R line completely reverted in sensitivity to 5-FU, with an IC50 of 1.7 μM. The resistant DLD-Ad line was 3.5-fold more resistant to 5-FU than was the parent DLD-1 line. Using both the 5-fluoro-2'-deoxyuridine-5'-monophosphate binding and catalytic assays for measurement of thymidylate synthase (TS) activity, there was significantly increased TS activity in the resistant MCF-Ad5 (2.4 and 2.5-fold), MCF-Ad10 (11.5- and 6.8-fold), and DLD-Ad (4.8- and 10.7-fold) lines, for binding and catalytic assays, respectively, compared with their parent MCF-7 and DLD-1 lines. The level of TS in cytosolic extracts, as determined by Western immunoblot analysis, was markedly increased for the resistant MCF-Ad5 (31-fold), MCF-Ad10 (46-fold), and DLD-Ad (52-fold) cells. Measurement of TS mRNA levels by Northern analysis revealed elevation of TS mRNA in the resistant MCF-AD5 (16.7-fold), MCF-Ad10 (31-fold), and DLD-Ad (55-fold) cells. Southern analysis showed that this increase in TS mRNA was not accompanied by any major rearrangements or amplification of the TS gene. Incorporation of 5-FU into the RNA and DNA of the resistant MCF-Ad10 cells was not significantly different, compared with that for parent MCF-7 cells. These studies suggest that exposure of human breast and human colon cancer cells to Adriamycin leads to overexpression of TS, with concomitant development of resistance to 5-FU.",
author = "E. Chu and Drake, {J. C.} and Koeller, {D. M.} and S. Zinn and Jamis-Dow, {Carlos Alberto} and Yeh, {G. C.} and Allegra, {C. J.}",
year = "1991",
month = "1",
day = "1",
language = "English (US)",
volume = "39",
pages = "136--143",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

Chu, E, Drake, JC, Koeller, DM, Zinn, S, Jamis-Dow, CA, Yeh, GC & Allegra, CJ 1991, 'Induction of thymidylate synthase associated with multidrug resistance in human breast and colon cancer cell lines', Molecular Pharmacology, vol. 39, no. 2, pp. 136-143.

Induction of thymidylate synthase associated with multidrug resistance in human breast and colon cancer cell lines. / Chu, E.; Drake, J. C.; Koeller, D. M.; Zinn, S.; Jamis-Dow, Carlos Alberto; Yeh, G. C.; Allegra, C. J.

In: Molecular Pharmacology, Vol. 39, No. 2, 01.01.1991, p. 136-143.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Induction of thymidylate synthase associated with multidrug resistance in human breast and colon cancer cell lines

AU - Chu, E.

AU - Drake, J. C.

AU - Koeller, D. M.

AU - Zinn, S.

AU - Jamis-Dow, Carlos Alberto

AU - Yeh, G. C.

AU - Allegra, C. J.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - A series of Adriamycin-resistant human breast MCF-7 and human colon DLD-1 cancer cell lines were established by stepwise selection. The concentration of Adriamycin required to inhibit cell proliferation by 50% (IC50) in the parent breast line (MCF-7), Adriamycin-resistant lines (MCF-Ad5 and MCF-Adl 0), and a 5-fluorouracil (5-FU)-revertant line (MCF-R) was 0.005, 3.3, 6, and 4.9 μM, respectively. The Adriamycin IC50 value for the resistant colon line (DLD-Ad) was 8.2 μM, 68-fold higher than that for its parent line (DLD-1) (IC50 = 0.12 μM). The MCF-Ad5 and MCF-Ad10 cells were cross-resistant to 5-FU, with respective 5-FU IC50 values of 11.7 and 22.5 μM, or 7.3- and 14-fold less sensitive than their parent MCF-7 (IC50 = 1.6 μM) line. The MCF-R line completely reverted in sensitivity to 5-FU, with an IC50 of 1.7 μM. The resistant DLD-Ad line was 3.5-fold more resistant to 5-FU than was the parent DLD-1 line. Using both the 5-fluoro-2'-deoxyuridine-5'-monophosphate binding and catalytic assays for measurement of thymidylate synthase (TS) activity, there was significantly increased TS activity in the resistant MCF-Ad5 (2.4 and 2.5-fold), MCF-Ad10 (11.5- and 6.8-fold), and DLD-Ad (4.8- and 10.7-fold) lines, for binding and catalytic assays, respectively, compared with their parent MCF-7 and DLD-1 lines. The level of TS in cytosolic extracts, as determined by Western immunoblot analysis, was markedly increased for the resistant MCF-Ad5 (31-fold), MCF-Ad10 (46-fold), and DLD-Ad (52-fold) cells. Measurement of TS mRNA levels by Northern analysis revealed elevation of TS mRNA in the resistant MCF-AD5 (16.7-fold), MCF-Ad10 (31-fold), and DLD-Ad (55-fold) cells. Southern analysis showed that this increase in TS mRNA was not accompanied by any major rearrangements or amplification of the TS gene. Incorporation of 5-FU into the RNA and DNA of the resistant MCF-Ad10 cells was not significantly different, compared with that for parent MCF-7 cells. These studies suggest that exposure of human breast and human colon cancer cells to Adriamycin leads to overexpression of TS, with concomitant development of resistance to 5-FU.

AB - A series of Adriamycin-resistant human breast MCF-7 and human colon DLD-1 cancer cell lines were established by stepwise selection. The concentration of Adriamycin required to inhibit cell proliferation by 50% (IC50) in the parent breast line (MCF-7), Adriamycin-resistant lines (MCF-Ad5 and MCF-Adl 0), and a 5-fluorouracil (5-FU)-revertant line (MCF-R) was 0.005, 3.3, 6, and 4.9 μM, respectively. The Adriamycin IC50 value for the resistant colon line (DLD-Ad) was 8.2 μM, 68-fold higher than that for its parent line (DLD-1) (IC50 = 0.12 μM). The MCF-Ad5 and MCF-Ad10 cells were cross-resistant to 5-FU, with respective 5-FU IC50 values of 11.7 and 22.5 μM, or 7.3- and 14-fold less sensitive than their parent MCF-7 (IC50 = 1.6 μM) line. The MCF-R line completely reverted in sensitivity to 5-FU, with an IC50 of 1.7 μM. The resistant DLD-Ad line was 3.5-fold more resistant to 5-FU than was the parent DLD-1 line. Using both the 5-fluoro-2'-deoxyuridine-5'-monophosphate binding and catalytic assays for measurement of thymidylate synthase (TS) activity, there was significantly increased TS activity in the resistant MCF-Ad5 (2.4 and 2.5-fold), MCF-Ad10 (11.5- and 6.8-fold), and DLD-Ad (4.8- and 10.7-fold) lines, for binding and catalytic assays, respectively, compared with their parent MCF-7 and DLD-1 lines. The level of TS in cytosolic extracts, as determined by Western immunoblot analysis, was markedly increased for the resistant MCF-Ad5 (31-fold), MCF-Ad10 (46-fold), and DLD-Ad (52-fold) cells. Measurement of TS mRNA levels by Northern analysis revealed elevation of TS mRNA in the resistant MCF-AD5 (16.7-fold), MCF-Ad10 (31-fold), and DLD-Ad (55-fold) cells. Southern analysis showed that this increase in TS mRNA was not accompanied by any major rearrangements or amplification of the TS gene. Incorporation of 5-FU into the RNA and DNA of the resistant MCF-Ad10 cells was not significantly different, compared with that for parent MCF-7 cells. These studies suggest that exposure of human breast and human colon cancer cells to Adriamycin leads to overexpression of TS, with concomitant development of resistance to 5-FU.

UR - http://www.scopus.com/inward/record.url?scp=0026030052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026030052&partnerID=8YFLogxK

M3 - Article

C2 - 1704999

AN - SCOPUS:0026030052

VL - 39

SP - 136

EP - 143

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 2

ER -

Chu E, Drake JC, Koeller DM, Zinn S, Jamis-Dow CA, Yeh GC et al. Induction of thymidylate synthase associated with multidrug resistance in human breast and colon cancer cell lines. Molecular Pharmacology. 1991 Jan 1;39(2):136-143.